Thermo Fisher Scientific Inc., a maker of scientific instruments and related technologies, has paid $260 million in cash to acquire Fermentas International Inc., an Ontario, Canada-based maker and distributor of enzymes, kits and reagents for molecular and cellular biology research.
Adult digital artery imaged with a conventional high frequency linear transducer (200 micron resolution).
Image Source: SonoSite
SonoSite, a developer of point-of-care ultrasound systems, today signed an agreement to acquire privately held Visualsonics, a Toronto-based company focused on high-frequency micro-ultrasound technology, in a transaction approximately valued at $71 million net of cash and debt.
Cannasat Therapeutics (TSX-V), a specialty pharmaceutical company, has received the shareholder approval to change its corporate name to Cynapsus Therapeutics.
An international study based at the University of Pittsburgh has identified a human enzyme that can biodegrade carbon nanotubes. Laboratory tests showed that it could also offset the potentially damaging health effects of being exposed to such nanotechnology.
A federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property
With Healthcare legislation well on its way to ultimate approval and implementation, the winds are now calming and its becoming clearer what the tornado has left behind for the pharmaceutical industry. Many had feared it would result in permanent widespread damage, but it appears the storm may actually have carved a path toward greener pastures for the industry.
Interest is booming in the use of mobile devices such as Apple's iPhone for image viewing applications. But that excitement may be dampened somewhat with a recent U.S. Food and Drug Administration (FDA) decision to classify an iPhone image viewing application as a class III device requiring premarket approval.
The R&D investments by PhRMA members and non-members in the pharmaceutical and biotech sectors reached a record $65.3 billion in 2009, an increase of 1.5 billion
there are more than 2,900 medicines in clinical trials or awaiting review
The R&D investments by PhRMA members and non-members in the pharmaceutical and biotech sectors reached a record $65.3 billion in 2009, an increase of 1.5 billion despite the recession
Loblaw Companies Ltd. plans to install rooftop solar panels on its Innes Road store in Orleans as part of a pilot project that could see the grocery chain outfitting up to 136 of its Ontario locations with the renewable energy technology.